The European Food Safety Authority has taken a cautious step toward potentially opening the EU market to cannabis-derived food products, setting the stage for what could become a lucrative new sector while navigating complex regulatory and social sensitivities. The agency's scientific opinion directly impacts food manufacturers seeking to innovate with cannabis extracts, health-conscious consumers looking for new wellness products, and regulators balancing safety concerns with market development.
This assessment comes from EFSA's Scientific Opinion published on March 30, 2026, prepared by the agency's Panel on Nutrition, Novel Foods and Food Allergens (NDA). The document represents a non-binding scientific assessment rather than legislation, providing expert evaluation of safety data submitted by applicants seeking novel food authorization.
The opinion contains concrete scientific conclusions about safety parameters, including recommended maximum intake levels and specific conditions of use, rather than vague commitments. EFSA's assessment focuses on whether the cannabis CO2 extract meets established safety standards for human consumption when used in specified food categories.
The policy direction reveals a tension between market innovation in the food sector and consumer safety regulation. EFSA prioritizes rigorous scientific safety assessment over market access speed, emphasizing evidence-based evaluation of potential health risks associated with cannabis compounds. This represents a cautious approach to expanding the range of permitted novel foods, particularly for substances with psychoactive associations.
For cannabis extract producers, this represents a major opportunity to enter the EU food market if authorization follows, potentially creating a new revenue stream. However, they face significant compliance costs for safety testing and documentation. EU consumers gain potential access to new wellness products but must navigate complex labeling and dosage restrictions. National food safety authorities receive scientific guidance for their own regulatory decisions, reducing their assessment burden but potentially creating enforcement challenges. Traditional food manufacturers face new competition from cannabis-based products in wellness and functional food segments.
This scientific opinion represents the middle stage of the novel food authorization process. EFSA's assessment will now inform the European Commission's decision-making, with the Commission expected to propose implementing legislation. Member States will then vote on the proposal through the Standing Committee on Plants, Animals, Food and Feed, determining whether cannabis CO2 extract receives formal novel food authorization across the EU.
← Atlas › News